Analysts Are Updating Their 10x Genomics, Inc. (NASDAQ:TXG) Estimates After Its First-Quarter Results

FierceBiotechFosun pays $60M for option on AriBio’s phase 3 Alzheimer’s asset

BioPharma DiveAssertio accepts new buyout bid; AI biotech Isomorphic banks $2B

Endpoints NewsBehind Galapagos’ transformation into Lakefront Biotherapeutics

FierceBiotechValneva to lay off up to 15% of workforce in face of ‘adverse trend’ in travel vaccines

PharmaVoiceIndia’s pharma industry is going global. But can it catch up to China?

PharmaVoiceWhy the FDA’s push for real-time clinical trials could favor Big Pharma

LabiotechWhat investors now expect from AI biotech companies

BioWorldTracking hantavirus across the globe

FierceBiotechMedtronic to shutter Santa Rosa plant as it restructures cardio vascular unit

Endpoints NewsTessera reveals strongest data yet for in vivo sickle cell therapy

10x Genomics BlogAnalysts Are Updating Their 10x Genomics, Inc. (NASDAQ:TXG) Estimates After Its First-Quarter Results - simplywall.st

BioPharma Dive[Podcast] Closing the Distance in Cancer Care